Navigation Links
Leeds' St James's Institute of Oncology Acquires Two Elekta Versa HD Radiotherapy Systems
Date:5/27/2013

LEEDS, England, May 27, 2013 /PRNewswire/ -- St James's Institute of Oncology, a leading radiotherapy center in the UK, recently ordered two Versa HD™ systems, an advanced linear accelerator designed to improve patient care and treat a wide range of tumors throughout the body. As the latest, most sophisticated cancer treatment system on the market, Versa HD can help maximize health care resources. The system can deliver conventional therapies to a wide range of tumors throughout the body, while also permitting treatment of complex cancers that require extreme targeting accuracy.

St James's investigators performed extensive clinical studies with High Dose Rate mode and Elekta's 160-leaf multileaf collimator (Agility™), both critical components of Versa HD. Agility provides exceptional conformance of the radiation beam to the tumor, avoiding healthy tissue. In addition, the unique combination of Agility – with its rapid leaf speeds – and High Dose Rate mode enables rapid delivery of the radiation dose, enabling faster treatments. In their clinical studies of these integrated technologies, St James's researchers achieved substantial reductions in treatment times.

"These early experiences with Agility and High Dose Rate mode formed our decision to acquire two Versa HD systems at the earliest opportunity," says Vivian Cosgrove , Ph.D., Head of Radiotherapy Physics at St James's.

St James's first Versa HD will be ready to treat patients in July 2013, with the second system operational by the end of the year.

Lung and prostate cancers targeted

St James's clinicians foresee an important role for Versa HD in the treatment of inoperable lung cancer. The clinic has used hypofractionated lung stereotactic radiation therapy (SRT) since 2009, employing its Elekta technology extensively for these patients. Now, with Versa HD, St James's hopes to exploit the system's speed to further limit the likelihood of patient movement during treatment, thereby improving the accuracy and safety of SRT.

For its Versa HD systems, St James's will prioritize the treatment of these inoperable lung cancer patients, in addition to those with prostate cancer.

"We are managing a heavy workload of more than 7,000 new radiotherapy patients per year," says Kevin Franks , M.D., Consultant in Clinical Oncology at St James's. "The Versa HD systems will definitely enhance our treatment efficiency. In fact, we have an ambitious plan to treat over 60 patients per day on the first Versa HD installed in our department. Our initial experience indicates this is achievable."

"In addition to minimizing risk of irradiating healthy tissue, we also decrease treatment times, making it a much better experience for the patient," he adds. "Moreover, by reducing treatment times, we should be able to add more patients to the daily schedule, which will increase access to this technology for patients in Leeds and throughout Yorkshire."

For more information, visit www.VersaHD.com.

Versa HD is not for sale or distribution in all markets.

For further information, please contact:
Johan Andersson , Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com  
Time zone: CET: Central European Time

Michelle Joiner , Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. High Altitude Climbers at Risk for Brain Bleeds
2. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
3. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
4. RAD Technology Medical Systems Delivers Innovative Time Saving Modular Construction At New Swedish Cancer Institute Facility
5. Texas Institute for Robotic Surgery Among First in Nation To Perform Single-Site Robotic Hysterectomy Surgery
6. Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy Adds The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
7. Heritage-DREAM, National Cancer Institute Breast Cancer Network Inference Prize Announced
8. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
9. ECRI Institute Unveils Costs and Configurations for Top Hybrid OR Imaging Systems
10. Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials
11. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):